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Abstract
Background: Osteopontin (OPN) has been shown to play many roles in the progression of cancer. We have
recently demonstrated the activation of Akt by OPN. Integrin-linked kinase and PI3-kinase are integral proteins in
OPN/AKT pathway in PC3 cells. To investigate the role of the extracellular receptors in OPN signaling, we have
examined the spatio-temporal regulation of CD44 and integrin avb3 receptor in OPN-induced Akt activation in
PC3 cells.
Results: Here, our studies demonstrate that OPN can activate Akt either through the aVb3 integrin or the CD44
cell surface receptor. Members of the Mitogen Activated Protein Kinase (MAPK) family have been shown to be up-
regulated in a variety of human cancers and have been implicated in the metastatic behavior. Our studies have
demonstrated an increase in the phosphorylation of c-Raf at Ser259 and Ser338 in PC3 cells over-expressing OPN.
This increase matches up with the Erk1/2 phosphorylation at Thr202/204 and activation. However, the inhibition of
Akt activity augments the phosphorylation state of ERK1/2 to two to three fold with a concomitant reduction in
the phosphorylation state of c-Raf at Ser259.
Conclusions: Regulation c-Raf phosphorylation at Ser259 has a role in the anti-apoptotic pathways mediated by
Akt or Raf/MEK/ERK proteins. OPN may have dual effects in the activation of Erk1/2. We propose this based on the
observations that while OPN activates c-Raf and Erk1/2; it also acts to inhibit c-Raf and Erk1/2 activation through
Akt pathway. Our observations suggest that the activation of c-Raf-ERK cascade may promote cell cycle arrest in
prostate cancer cells and OPN signaling has a role in the anti-apoptotic mechanism.
Introduction
Osteopontin (OPN) is a multifunctional glycoprotein
expressed by a number of cell types. Osteopontin
expression has been linked to tumorigenesis and metas-
tasis in a wide range of cancer types including prostate,
breast, colon, melanoma, and lung [1]. Tumor bearing
prostates contained 3.2 fold higher OPN levels [2]. OPN
expression has been shown to be a prognostic indicator
of survival among patients with advanced cancer. Ele-
vated serum levels of OPN coincide with decreased sur-
vival rates among patients [3]. We have previously
demonstrated that OPN has a role in osteoclast bone
resorption [4] and prostate cancer cell migration [5],
survival [6], and invasion [7].
Osteopontin mediates biological function through sig-
nal transduction by binding to the cell surface receptors
such as integrin avb3 and CD44 [5]. It is an arginine-
glycine-aspartic acid (RGD) containing extracellular
matrix protein with diverse functions [8,9]. OPN inter-
action with integrin avb3 transduces cell-matrix signal-
ing directed to increased motility, invasion, and
angiogenesis [10]. Occupancy of RGD domain by avb3
elicits cell signaling required for cell migration and inva-
sion [10,11]. Integrin avb3a n dC D 4 4h a v ear o l ei nt h e
metastasis of prostate cancer cells to bone by arbitrating
adhesion to and migration on OPN protein present in
the bone microenvironment [10-12].
The CD44 family of receptors regulates in a manner
similar to that of integrins in cellular responses includ-
ing adhesion, migration, and the stimulation of both
cancerous and non-cancerous cells [13,14]. Our recent
studies have shown an increase in the surface expression
of CD44 isoforms (sCD44 and v4-v10 variant CD44) in
prostate cancer cells over-expressing osteopontin (PC3/
OPN) [15]. PC3 cells exhibited a rapid and strong
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(hBMECs), and depletion of CD44 expression by RNAi
attenuated this adhesion [16]. Our most recent studies
in prostate cancer cells demonstrate that OPN can acti-
vate Akt, an important step in cancer progression. An
overall increase in b-catenin protein levels with a resul-
tant transfer of b-catenin to the nucleus was observed
in cells treated with or over-expressing OPN. Through
the nuclear import of b-catenin, OPN increases both the
transcription and protein levels of MMP-7 and CD44,
which are known TCF/LEF transcription targets [6].
The Erk pathway is one of the best studied MAPK
pathways in mammals and has been shown to be
deregulated in approximately one-third of all human
cancers [17]. Erk1/2 activation regulates proliferation,
differentiation, survival, migration, angiogenesis, and
even chromatin remodeling through the phosphorylation
of both cytoplasmic and nuclear targets including phos-
phatases, transcriptional factors, and cytoskeletal pro-
teins [17]. In the canonical Erk1/2 pathway, receptor
tyrosine kinases are activated by specific ligands and
trigger guanosine trisphosphate (GTP) loading of the
Ras protein, which can then recruit the Raf kinases (A-
Raf, B-Raf, c-Raf). These kinases consecutively phos-
phorylates and activates MEK (MEK 1 and MEK 2), ulti-
mately leading to the activation of Erk1/2. In addition to
this pathway, Erk1/2 has been shown to be activated by
a variety of pathways depending on the individual
ligand, cell surface receptor, and cell type [17]. Das et al.
previously demonstrated that OPN induces AP-1 activa-
tion and uPA secretion through c-Src/EGFR/Erk signal-
ing in breast cancer cells which ultimately control the
motility in these cells [18]. Due to the existence of wide
variation in the pathways leading to Erk1/2 activation,
we investigated the OPN induced signaling pathway(s)
which lead to Erk1/2 activation in prostate cancer cells
and the role of cell surface receptors (avb3a n dC D 4 4 )
in this process.
Raf is targeted to the plasma membrane upon activa-
tion by a small GTPase. Phosphorylation of c-Raf at ser-
ine 259 is an inhibitory event occurring through Akt
[19]. Previous studies have shown that osteoclast survi-
val is dependent on the Erk1/2 signaling pathway [20].
Increased osteoclast production and activity contributes
to excessive bone loss in conditions such as osteoporosis
and tumor-induced osteolysis [20], which has been
linked to prostate cancer [21]. Because prostate cancer
results in metastases to the bone in approximately 80%
of autopsied cases, prostate cancer cells present a logical
system in which to study the relationships of bone
extracellular matrix proteins and tumorigenesis [22].
OPN acts as a paracrine and autocrine mediator of
prostate cancer growth and progression [11]. OPN role
in the activation of MAPK pathway needs further
elucidation. Therefore, we sought to determine how
OPN promotes activation of the Erk pathway to induce
cell proliferation. We have investigated the role of integ-
rin avb3, CD44, and Akt by using SiRNA to CD44 and
specific inhibitors to AKT and av. We show here that
elevated levels of OPN expression in prostate cancer
cells stimulate Akt and Raf/MEK/ERK signaling path-
ways in order to produce different effects on prolifera-
tion and survival (anti-apoptosis).
Results
Osteopontin induces Erk1/2 activation
We measured the phosphorylation state of the three
most widely known members of the mitogen-activated
kinase (MAPK) family proteins including Erk1/2, JNK,
or p38 MAPK in PC3 cells over expressing OPN (PC3/
OPN). Stable PC3/OPN cells were generated as
described previously [5]. PC3/OPN stable cell lines dis-
play an increased expression of OPN compared with
stable PC3 cell lines expressing empty vector (Figure
1A, lane 2). Previous studies have shown that metastatic
PC3 and DU145 prostate cancer cells have relatively
low levels of active Erk1/2 [23]. Western blot analysis
with indicated phosphor-specific antibody was per-
formed. Consistent with those findings, we show here
that PC3 cells expressing pCEP4 vector (henceforth
represented as PC3) displayed either minimal or barely
detectable levels of phosphorylation of Erk 1/2 (Figure
1B, lane 1). The phosphorylation is increased to a
greater extent in PC3/OPN cells (Figure 1C, lane 2). An
increase in the phosphorylation at Thr 202/204 repre-
sents the activation of Erk1/2 in PC3/OPN cells (Figure
1B, lane 2). Confocal analysis of PC3 and PC3/OPN
cells stained for phospho-Erk1/2 also revealed a robust
and diffuse staining of activated Erk1/2 in PC3/OPN
cells (Figure 1E, bottom middle panel). An increased
staining substantiates the activation of Erk1/2 in PC3/
OPN cells since staining was performed with phosphor-
Erk1/2 antibody. PC3 cells show sparse staining of
phospho- Erk1/2 (Figure 1E, Top middle panel, green).
This is consistent with the immunoblotting analysis
shown in Figure 1B which demonstrates a decrease in
the phosphorylation and activation of Erk1/2 in PC3
cells. Actin staining was used to demonstrate the cell
periphery.
Immunoblotting analyses demonstrated a small
increase in the phosphorylation of JNK at Threonine
183 and Tyrosine 185 in PC3/OPN cells (Figure 1C,
lane 2). Furthermore, OPN had a very negligible effect
on the phosphorylation of p38 MAPK at Thr180/Tyr182
(Figure 1D, lane 2). GAPDH was used as a loading con-
trol when probing total OPN expression levels (Figure
1A; lower panel). There were no observed differences in
the protein levels of non-phosphorylated MAPK family
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1B-D; lower panels).
Osteopontin induced Erk1/2 activation occurs through
c-Raf and MEK1/2
Raf and MEK have been shown to be the upstream
regulators of Erk1/2 [17]. In order to determine the role
of Raf and MEK1/2 in OPN-mediated activation of
Erk1/2, western blot analysis was employed. Structures
of the Raf proteins (A-Raf, B-Raf, and c-Raf) have been
shown to be similar, but the proteins maintain differ-
ences in how they are activated and how they activate
downstream targets such as MEK1/2 [17]. Activation of
A-Raf and B-Raf is represented by the phosphorylation
at Ser 299 and 245, respectively. Activation of c-Raf is
measured by phosphorylation at Ser 338 [24]. Phosphor-
ylation of A-Raf was almost not detected in PC3 and
PC3/OPN cells (Figure 2A). Conversely, PC3 cells exhib-
ited a higher basal level phosphorylation of B-Raf at
Ser445 in PC3 cells (lane 1) and OPN expression had
no effect in increasing the phosphorylation state of
B-Raf (Figure 2B, lane 2). However, activation of c-Raf
appears to highly dependent on OPN over-expression
(Figure 2C, lane 2). An increase in the phosphorylation
of c-Raf at Ser338 suggests that activation of c-Raf may
have a role in the OPN-dependent Raf/MEK/ERK path-
way and control apoptosis. Therefore we next proceed
to investigate the activation of MEK1/2 in response to
OPN over-expression. MEK1/2 activation is character-
ized by phosphorylation at two activation loop residues,
Ser 217 and Ser 221. We found an increase in the acti-
vation of MEK1/2 in PC3/OPN cells as compared to
PC3 control cells (Figure 2D).
Akt negatively regulate Erk 1/2 activation in PC3/OPN
cells
Recent observations have demonstrated an increase in
the activation of Akt in PC3/OPN cells [6,25]. Little is
known about the role of Akt in the Erk pathway in PC3
cells. Therefore, we have investigated the effects of Akt
inhibitor on the phosphorylation of c-Raf and ERK1/2
on Thr202/204. OPN expression in PC3 cells increased
Akt activation, as measured the phosphorylation of
ser473 (Figure 3A, lane 2). Serine 259 of c-Raf has been
shown to be regulated by Akt. Its phosphorylation pro-
vides a docking site for the cytosolic protein 14-3-3 and
the subsequent inhibition of c-Raf activation [17]. OPN,
presumably through Akt induces the phosphorylation of
Figure 1 OPN induces Erk1/2 activation. Lysates from PC3 and PC3/OPN cell lines were immunoblotted with phospho-specific antibodies to
OPN, Erk1/2, JNK, and p-38 (A-D, upper panels) proteins. Immunoblotting with the corresponding non-phosphorylated antibodies demonstrates
equal loading of indicated proteins (A-D, lower panels). Confocal microscopy analysis of distribution of actin (red) and phospho-Erk1/2 (green) in
PC3 and PC3/OPN cell lines is shown in Panel E. Results shown are representative of three independent experiments.
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inhibitor showed an almost undetectable amount of
c-Raf phosphorylation at ser259 (Figure 3C, lane 2)
when compared with vehicle treated PC3 cells (Figure
3C, lane 1). In order to more fully understand the role
of OPN in c-Raf activation and its association with Akt,
the activation of Erk1/2 and c-Raf was studied in the
presence of Akt inhibitor (Figure 3D and 3E). In the
presence of an Akt inhibitor, PC3/OPN cells displayed a
further increase in phosphorylation of c-Raf at Ser338
(lane 4 in Figure 1D) and Erk1/2 at Thr202/204 (Figure
3E, lane 4) as measured by immunoblotting analyses
with respective phospho-specific antibody. These results
indicate that while OPN ultimately activates c-Raf and
Erk1/2, its activation of Akt plays an inhibitory role
through the increased phosphorylation of c-Raf Serine
259, a known docking site for 14-3-3 protein.
OPN induces activation of Akt through both aVb3
integrins and the CD44 cell surface receptor
Integrin avb3 and CD44 are receptors of osteopontin
and CD44 is frequently over expressed in cancer cells
[13]. To assess whether both the CD44 and aVb3 recep-
tors have a role in OPN- mediated Akt activation, we
used a specific inhibitor (cyclo RGD; Figure 4A and 4D)
to the aVb3 integrin and siRNA to CD44 (Figure 4B
and 4C). PC3 cells over expressing OPN with a muta-
tion in the integrin binding domain RGDΔRGA
(referred to as PC3/RGA) and thus no longer able to
activate integrins were used to further define the
Figure 2 OPN induces activation of c-Raf and MEK1/2. Protein lysates from PC3 and PC3/OPN cell lines were immunoblotted with phospho-
specific antibodies of A-Raf, B-Raf, c-Raf, and MEK1/2 (upper panels in A-D). Immunoblotting with the corresponding non-phosphorylated
antibodies (lower panels in A-C) or GAPDH antibody (lower panel in D) was used to demonstrate equal loading. Results shown are
representative of three independent experiments.
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activation of Akt. The expression levels OPN and OPN
(RGA) in these cell lines were shown previously. We do
not see any differences in the molecular mass of cellular
or secreted OPN in PC3, PC3/OPN or PC3/OPN (RGA)
cells. The molecular mass of native OPN protein is
approximately 30-36 kDa. These cells express ~60-68
kDa OPN protein which indicates that OPN is glycosy-
lated [5]. PC3/OPN and PC3/RGA cells increase Akt
activation (Figure 4A and 4C; lanes 2 and 3) when com-
pared with PC3 cells, suggesting that OPN can induce
activation of Akt in the absence of integrin signaling
( F i g u r e4 Aa n d4 C ,l a n e1 ) .I nt h ep r e s e n c eo ft h eaV
inhibitor, PC3/OPN cells no longer have the ability to
induce activation of Akt (Figure 4A, lane 6), while
expression of mutant OPN in PC3 cells (PC3/RGA) did
not affect the phosphorylation of Akt (Figure 4A, lane
5). The ability of PC3/RGA cells to activate Akt in the
presence of the aV inhibitor suggests a role for an addi-
tional receptor.
CD44 is another receptor for OPN [13] and previous
work from our laboratory showed that CD44 has an
important role in the activation of MMP-9 and migra-
tion of PC3 cells [5]. Therefore, we sought to determine
the role of CD44 in the activation of Akt using CD44
knock-down strategy with SiRNA to standard (s)CD44
( F i g u r e4 B - E ) .W ea r r i v e da ta b o u t7 5 - 8 5 %k n o c k d o w n
of sCD44 when using SiRNA to sCD44 (Figure 4B, lane
2). Scrambled RNAi was used as a control (lane 1).
Mutation in OPN (RGA) abolishes Akt activation only
in the cells depleted of CD44 (Figure 4C, lane 5) while
PC3/OPN cells retain the ability to induce Akt activa-
tion, presumably through the interaction of aVb3a n d
OPN via RGD-sequence (lane 6). However, cells treated
with SiRNA to CD44 and an inhibitor to avd e m o n -
strated a considerable decrease of both CD44 and aVb3
integrin-mediated Akt activation (Figure 4E, lane 6). A
graphical representation of changes in AKT phosphory-
lation (i.e. activation) is provided (Figure 4E) for the
Western blot shown in Figure 4D. Cells treated with
Figure 3 Phosphorylation of OPN induced Erk1/2 and c-Raf activation by Akt. (A) PC3 and PC3/OPN cells were immunoblotted with an Akt
phospho-specific antibody (Akt-Ser473, upper panel). Membrane was stripped and blotted with an antibody to Akt to demonstrate total levels of
AKT and equal loading (bottom panel). (B) PC3 and PC3/OPN cells were immunoblotted with an antibody to c-Raf Serine 259 (upper panel) and
equal loading was shown using total levels of c-Raf (bottom panel). (C) PC3 cells were treated with either a vehicle or an Akt inhibitor overnight
and immunoblotted with a phospho-specific antibody to c-Raf (Ser 259). (D and E) PC3 and PC3/OPN cell lines were pretreated with an Akt
inhibitor for 16 h. The cell lysates were immunoblotted with phospho-specific antibodies to Erk1/2 (Thr202/204) or c-Raf (Ser338; upper panels in
D and E). Membrane was stripped and immunoblotted with the corresponding non-phosphorylated antibodies to Erk1/2 and c-Raf to
demonstrate equal protein loading (D and E-bottom panels). Results are representative of three independent experiments.
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to the corresponding control cells untreated with av-
inhibitor but treated with scrambled RNAi (Figure 4E).
These experiments illustrate that the interaction
between OPN and either CD44 or integrin is sufficient
to induce phosphorylation of Akt, which is largely
responsible for the anti-apoptotic mechanisms vital to
cancer cell survival and progression.
Discussion
The ability of OPN to induce phosphorylation and acti-
vation of Erk1/2 represents a novel and important sig-
naling mechanism in prostate cancer progression. Here
we have identified that the increased expression of OPN
leads to the activation of the Erk1/2 (Figure 1). Lack of
OPN-mediated activation of JNK and p-38 proteins
demonstrates that OPN does not stimulate the signaling
pathways associated with these proteins. Signaling path-
way analysis has revealed that Erk1/2 can be activated
by a variety of upstream kinases and that each event is
dependent on the specific ligand and cell type used
[23,24]. The Raf/MEK/ERK cascade is known to be criti-
cally important in the regulation and growth of a variety
of cells [26,27]. Previous studies have shown that inhibi-
tion of MEK1/2 resulted in the inhibition of Erk1/2 acti-
vation [17]. MEK1/2 was shown to be activated upon
OPN over-expression and, due to the established role of
MEK in Erk activation, we propose that this appears to
be an important intermediary step in OPN-induced
Erk1/2 activation (Figure 1). Of the Raf- family of pro-
teins, increase in the phosphorylation of c-Raf at 338
represent an increase in the activation of this protein in
the PC3/OPN cell line as compared with A-Raf and B-
Raf. It seems that these proteins do not have a notable
role in OPN mediated Erk1/2 signaling.
To further elucidate OPN signaling, we investigated
the role of Akt in OPN mediated Erk1/2 activation. It
has been shown that Akt plays an inhibitory role in
Figure 4 Osteopontin induces activation of Akt through aVb3 integrins and CD44. Different PC3 cell lines (PC3, PC3/OPN, and PC3/RGA)
were treated with and without aV integrin inhibitor (Cyclo-RGD, 10 μM for 16 h (panel A), siRNA to CD44 (200 nM for 48 hr; panels B and C), or
a combination of both the aV integrin inhibitor and CD44 siRNA (panel D). The effects of inhibitors on Akt activation or phosphorylation were
determined by immunoblotting analysis (upper panels, A-D). Total Akt levels were used as loading controls (lower panels in A, C, and D).
Immunoblotting with a GAPDH antibody indicates equal loading in panel B. Changes in Akt phosphorylation levels were normalized to
respective control on the Western blot shown in D and represented as fold change in the graph (Figure E). Graph E is a quantitative
representation of the single western blot shown in panel D. Immunoblotting results are representative of three independent experiments.
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ylation of c-Raf at ser259, which facilitates the binding
of 14-3-3 proteins [28]. We observed that the activation
of Akt by OPN results in the phosphorylation of c-
Raf259, which inhibits c-Raf activity and also decreases
Erk1/2 activation (Figure 3). PC3/OPN cells treated with
Akt inhibitor reveal an increase in the activation of
Erk1/2 and c-Raf338 suggesting that Akt is acting as a
negative regulator of Erk1/2 activation (Figure 3).
Together, our results indicate that OPN has dual effects
in the anti-apoptotic pathway. Osteopontin activates c-
Raf and Erk1/2, while it also acts to inhibit c-Raf and
Erk1/2 activation through Akt pathway.
Although high levels of active Akt are present in PC3
cells in the absence of OPN over-expression, we choose
the PC3 cell line as a model system because they con-
tain the cell surface receptors CD44 and aVb3 integrins.
We considered that this is the best model system to
investigate the signaling interactions between OPN and
each of these two surface receptors. The use of the
cyclo-RGD molecular inhibitor of avb3a n dS i R N At o
CD44 in PC3 cell lines in combination with the use
untreated (-) PC3 cell lines (over-expressing either full-
length or mutated (RGDΔRGA) OPN) in figure 4 indi-
cate that OPN can stimulate Akt activity through either
avb3o rC D 4 4r e c e p t o r s( F i g u r e4 ) .U p o nm u t a t i o no f
the RGDΔRGA region, OPN still retains the ability to
induce Akt activation presumably due to its interaction
with CD44. Osteopontin is a ligand for several cell sur-
face receptors, including avb3, avb1, a9b1, a4b1, a8b3,
and CD44 [8,14]. To rule out the role of any additional
surface receptors, we employed a combination of both
CD44 siRNA and aVb3 integrin inhibitor and observed a
loss Akt activation, indicating that binding of OPN to
integrins other than aVb3 does not result in a detect-
able level of Akt activation (Figure 4D). OPN binds to
PC3 cells by means of the CD44 receptor and integrin
aVb3 at the plasma membrane in an arginine-glycine-
aspartic acid (RGD) independent and dependent man-
ner, respectively. A schematic diagram is provided as
Figure 5 to demonstrate the role of OPN signaling in
the anti-apoptotic mechanism.
Androgen-independent advanced prostate cancer cell
lines such as DU145 and PC3 typically express low
levels of activated Raf, MEK,a n dE R K[ 2 9 ] .I nc o n t r a s t
to prostate cancer cells, breast cancer and hematopoietic
cancer are typically associated with increased levels of
Raf activation leading to increased proliferation and
drug resistance. McCubrey et al. suggests that Raf/MEK/
ERK may promote cell cycle arrest in prostate cancer
cells and this may be regulated by p53 restoration
[30,31]. Because introduction of wild type p53 into cell
Figure 5 Schematic model of signaling events of OPN induced Erk1/2 activation in prostate cancer cells.O P Nb i n d st oP C 3c e l l sb y
means of the CD44 receptor and integrins at the plasma membrane. Here we show that OPN phosphorylates c-Raf (Ser 338), a marker of c-Raf
activation, leading to downstream activation of MEK1/2. OPN activates Akt as well. Akt activity has been shown to phosphorylate c-Raf (Serine
259) which is an inhibitory site of the Raf proteins therefore blocking increased activation of c-Raf. Thus, although OPN induces overall Erk1/2
activation, it also has an inhibitory effect on Erk1/2 through the activation of Akt.
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DU145 cell lines increases both the cells sensitivity to
chemotherapeutic drugs and expression and activation
of the Raf/MEK/ERK cascades [30,31]. Some have pos-
tulated that therapies aimed at increasing Raf activation
may induce terminal differentiating senescence or cell
cycle arrest in certain prostate cancers [32]. In advanced
cancer it may be advantageous to induce Erk1/2 activa-
tion in order to promote cell cycle arrest, while in
hematopoietic cancers it may be beneficial to inhibit Raf
induced proliferation and drug resistance. Better under-
standing of how OPN works in tumorigenesis and in
the MAPK signaling pathways may give insight into
improved diagnosis, treatment, and prognosis of cancer.
Methods
Reagents
Monoclonal rabbit anti-phospho-p44/42MAPK (Erk1/2)
(Thr202/Tyr204), anti-phospho-SAPK/JNK (Thr183/
Tyr185), anti-phospho-c-Raf (Ser338), anti-p44/
42MAPK (Erk1/2), anti-B-Raf, polyclonal rabbit anti-
phospho-p38MAPK (Thr180/Tyr182), anti-phospho-c-
Raf (Ser259), anti-phospho-c-Raf (Ser289/296/301), anti-
phospho-A-Raf (Ser299), anti-phospho-B-Raf (Ser445),
anti-p38MAPK, anti-SAPK/JNK, anti-A-Raf, and anti-c-
Raf were purchased from Cell Signaling Technology
(Danvers, MA). GAPDH and CD44 antibodies were pur-
chased from Santa Cruz Biotechnology Inc (Santa Cruz,
CA). OPN antibody was purchased from Rockland
Immunochemicals (Gilbertsville, PA). Roswell Park
Memorial Institute-1640 (RPMI-1640) media, fetal
bovine serum (FBS), penicillin-streptomycin (10,000
units/ml penicillin and 10,000 μg/ml streptomycin),
0.25% Trypsin-EDTA, and phosphate buffered saline
(PBS) pH 7.4 were purchased from Invitrogen (GIBCO;
Auckland, NZ). Akt (5 μM) inhibitor, rhodamine phal-
loidin, and other chemicals were purchased from Sigma-
A l d r i c h( S t .L o u i s ,M O ) .P r o t e i na s s a yr e a g e n tk i t ,
reagents for polyacrylamide gel electrophoresis (PAGE),
and molecular weight standards were purchased from
Bio-Rad (Hercules, CA). Polyvinyldifluoride (PVDF)
membrane for immunoblotting analysis was obtained
from Millipore Corp. (Bedford, MA).
Cell culture
Stable prostate cancer cell (PC3) lines that either over
express unmutated OPN (PC3/OPN) or a mutant OPN
in the integrin-binding site (PC3/RGDΔRGA) was gen-
erated as described previously [5]. PC3 cells transfected
with empty pCEP4 vector were used as control. Cells
were cultured at 37°C in RPMI-1640 media containing
10% Fetal Bovine Serum (FBS) and 1% Penicillin-Strep-
tomycin. Upon reaching 100% confluency, cells were
passaged with two brief phosphate buffered saline (PBS)
washes, removed from tissue culture plates using 0.25%
Trypsin-EDTA, and transferred to larger dishes.
Preparation of cell lysates
Cells were washed two times with cold PBS and lysed in
ice-cold RIPA lysis buffer (10 mM Tris-HCl, pH 7.2,
150 mM NaCl, 1% deoxycholate, 1% Triton X-100, 0.1%
SDS, 1% aprotinin, 2 mM phenylmethysulfonyl fluoride,
and 0.6 mM sodium orthovanadate). After incubating
on ice for 10 min, lysates were centrifuged for 5 min at
6,000 rpm at 4°C. The supernatants were saved and pro-
tein concentrations were measured using the Bio-Rad
protein assay reagent kit.
Treatment of cells with inhibitors and immunoblotting
with phospho-specific antibodies
PC3 cell lines (PC3, PC3/OPN, and PC3/OPN (RGA)
were cultured in a 6-well culture dish and then treated
with one of the following inhibitor in the presence of
RPMI-1640 media containing 10% FBS at 37°C: Akt
inhibitor for 16 h (1:500 dilution of 5 μM stock), aV
integrin inhibitor (Cyclo-RGD, 10 μMf o r1 6h ) ,s i R N A
to CD44 (200 nM for 48 h). CD44 siRNA (product
number sc-29342) and scrambled siRNA (product num-
ber sc-37007) nucleotides were purchased from Santa
Cruz Biotechnology Inc (Santa Cruz, CA). siRNA trans-
fection reagent, RNAiFect, was purchased from Qiagen
(Valencia, CA). Protein lysates were subjected to 12%
SDS-PAGE and Western blot analysis as described
below.
Western blot analysis
Cell lysates were denatured by boiling for 5 minutes in
Novagen 1× SDS sample buffer (EMD Biosciences, Inc.
Madison, WI). Proteins were resolved by SDS-polyacry-
lamide gel electrophoresis on 8% or 12% gels and then
transferred to PVDF membranes. The membranes were
initially blocked with PBS containing 0.05% TWEEN 20
(PBS-T) and 5% BSA for 1 h at room temperature (RT)
and were then probed overnight at 4°C using a dilution
of 1:1000 with the following primary antibodies in PBS-
Ta n d5 %B S A :a n t i - p h o s p ho-p44/42MAPK (Erk1/2)
(Thr202/Tyr204), anti-phospho-SAPK/JNK (Thr183/
Tyr185), anti-phospho-c-Raf (Ser338), anti-phospho-
p38MAPK (Thr180/Tyr182), anti-phospho-c-Raf
(Ser259), anti-phospho-c-Raf (Ser289/296/301), anti-
phospho-A-Raf (Ser299), and anti-phospho-b-Raf
(Ser445). After three washes with PBS-T for 5 minutes
each, the membranes were incubated with a 1:1000
dilution of species-specific horseradish peroxidase
(HRP)- linked secondary antibody (Little Chalfont, UK)
in PBS-T and 5% blotting grade blocker non-fat dry
milk (Bio-Rad, Hercules, CA) for 2 h at RT. Blots were
washed three times with PBS-T for 15 min. each.
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Page 8 of 10Protein bands were visualized by chemiluminescence
using a SuperSignal West Pico Chemiluminescent Sub-
strate Kit (Thermoscientific, Rockford, IL). PVDF mem-
branes were stored in PBS-T at 4°C until being stripped
and re-probed with the corresponding control antibodies
to determine the loading in each lane as described
below.
Stripping and reprobing of membrane with antibody of
interest
The PVDF membranes were incubated in stripping buf-
fer (2% sodium dodecyl sulfate (SDS), 62.5 mM Tris
HCl pH 7.2, and 100 mM b-mercaptoethanol) at 55°C
for 15 min. After three washes with PBS-T for 15 min-
utes each, the membranes were blocked with PBS-T and
5% blotting grade blocker non-fat dry milk (Bio-Rad,
Hercules, CA) for 1 h at room temperature (RT) and
were then probed overnight at 4°C using a dilution of
1:1000 of the primary antibody of interest (e.g. anti-
GAPDH at 1:1000 dilution) in PBS-T and 5% blotting
grade blocker non-fat dry milk. The membranes were
washed three times with PBS-T for 5 min each and
were then incubated with a 1:1000 dilution of species-
specific horse-radish peroxidase (HRP-) linked second-
a r ya n t i b o d yi nP B S - Ta n d5 %b l o t t i n gg r a d eb l o c k e r
non-fat dry milk (Bio-Rad, Hercules, CA) for 3 h at RT.
Membranes were washed and proteins bands were
visualized as described above.
Immunostaining analysis
PC3 and PC3/OPN cells were cultured onto cover slips
in a 12-well dish for 14-16 h at 37°C. Cells were
washed three times with room temperature PBS (RT-
PBS) and fixed in 4% formaldehyde-PBS for 10 min.
After washing three times with RT-PBS, cells were per-
meabilized with 0.5% Triton X-PBS for 10 min. Cells
were washed three times with RT-PBS, followed by
incubation in 5% boiled goat serum for 1 h at RT.
After washing three times with RT-PBS, cells were
incubated with a 1:100 dilution of anti-phospho-p-44/
42(ERK1/2) (Thr202/Tyr204) in 5% boiled goat serum
overnight at 4°C. Cells were washed three times with
RT-PBS. Subsequently, cells were incubated for 3 h at
RT in the dark with the following: 1:1000 dilution of
FITC-conjugated species specific secondary antibody
and 1:500 dilution of rhodamine phalloidin for actin
staining. Cells were washed three times with RT-PBS
for 15 minutes each and the cover slips were trans-
ferred cell side down onto glass slides containing
perma fluor mounting medium (Thermo Scientific,
Pittsburgh, PA) and sealed with clear nail polish
around the edge of the cover slips. The immunostained
cells were viewed and photomicrographed on a Bio-
Rad 6000 (Hercules, CA) confocal microscope. Images
were stored in TIF image format and processed by the
Adobe Photoshop software program (Adobe Systems,
Inc., Mountain View, CA).
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